cabazitaxel
Jump to navigation
Jump to search
Introduction
FDA-approved 2010
Indications
- advanced androgen-insensitive prostate cancer
Dosage
- 25 mg/m2 every 3 weeks
- up to 10 cycles
- given in conjunction with prednisone 10 mg/day
Adverse effects
- diarrhea
- neutropenia, including febrile neutropenia
- increased risk of death within 30 days of last dose
Mechanism of action
- binds tubulin
More general terms
References
- ↑ de Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010 Oct 2; 376:1147. PMID: https://pubmed.ncbi.nlm.nih.gov/20888992